Pancreatic Extracts in The Treatment of Diabetes Mellitus

Banting, F. G.; Best, C. H.; Collip, J. B.; Campbell, Walter R.; Fletcher, A. A.

doi:10.2337/diab.5.1.69

Cited by 165 publications

(184 citation statements)

References 1 publication

(1 reference statement)

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…With the discovery of extraction and administration of insulin in type 1 diabetes patients by Banting et al [10] in 1922, the overall quality of life improved for diabetes patients and there has been a decrease in morbidity and mortality. This was a novel idea and lifesaving discovery at that time, but the idea and initial attempts of islet transplantation from pancreatic tissue precluded it by 30 years.…”

Section: Islet Transplantation Historymentioning

confidence: 98%

See 1 more Smart Citation

History of islet transplantation

Digon

2009

Curr Diab Rep

View full text Add to dashboard Cite

Patients with a diagnosis of type 1 diabetes mellitus endure stringent life-long medical therapy through the use of insulin to prevent end organ complications and maintain normoglycemia. However, some patients still suffer from hypoglycemic unawareness, even under intensive therapy. Within the past decade, noble efforts have been attempted to provide normoglycemia through cadaveric islet of Langerhans transplantation in order to reach a physiologic response. This effort, which has evolved for more than a century, actually predates the discovery of insulin.

show abstract

Section: Islet Transplantation Historymentioning

confidence: 98%

“…Autologous canine pancreatic tissue graft [11] 1894 Xenotransplantation of pancreatic tissue to a ketoacidotic child [12] 1922 Discovery of insulin [10] 1989…”

Section: Disclosurementioning

confidence: 99%

History of islet transplantation

Digon

2009

Curr Diab Rep

View full text Add to dashboard Cite

show abstract

“…Initially, von Mering and Minkowski (1889) reported that the removal of the pancreas produced a diabetic phenotype; it was subsequently found that crude pancreatic extracts produced moderate reductions in glycosuria (Piper, Allen, & Murlin, 1923). Then, in their ground-breaking work, Banting and Best (Banting, Best, Collip, Campbell, & Fletcher, 1922) demonstrated that insulin, isolated from pancreatic islets, could provide successful clinical treatment of type-1 diabetes. Insulin, purified from animal sources, rapidly became commercially available for the treatment of insulin-deficient (type-1) diabetes mellitus (Swann, 1986).…”

Section: Insulin Synthesis Secretion and Actionmentioning

confidence: 99%

Insulin Transport into the Brain and Cerebrospinal Fluid

Begg

2015

Hormones and Transport Systems

View full text Add to dashboard Cite

“…The establishment of functional genomic technologies in therapeutics has addressed questions concerning the tissue specificity of the protein of interest as well as the level of protein(s) under normal and diseased states (1). One of the first and best examples of metabolic diseases efficiently treated with a protein therapeutic (PT) was the juvenille diabetes mellitus in 1922 (2). Recombinant DNA technology permitted the expression of human insulin gene in Escherichia coli (E. coli) bacteria cells (3).…”

Section: Introductionmentioning

confidence: 99%

Transduction of Human Recombinant Proteins into Mitochondria as a Protein Therapeutic Approach for Mitochondrial Disorders

Papadopoulou

Tsiftsoglou

2011

Pharm Res

View full text Add to dashboard Cite

Protein therapy is considered an alternative approach to gene therapy for treatment of genetic-metabolic disorders. Human protein therapeutics (PTs), developed via recombinant DNA technology and used for the treatment of these illnesses, act upon membrane-bound receptors to achieve their pharmacological response. On the contrary, proteins that normally act inside the cells cannot be developed as PTs in the conventional way, since they are not able to "cross" the plasma membrane. Furthermore, in mitochondrial disorders, attributed either to depleted or malfunctioned mitochondrial proteins, PTs should also have to reach the subcellular mitochondria to exert their therapeutic potential. Nowadays, there is no effective therapy for mitochondrial disorders. The development of PTs, however, via the Protein Transduction Domain (PTD) technology offered new opportunities for the deliberate delivery of human recombinant proteins inside eukaryotic subcellular organelles. To this end, mitochondrial disorders could be clinically encountered with the delivery of human mitochondrial proteins (engineered via recombinant DNA and PTD technologies) at specific intramitochondrial sites to exert their function. Overall, PTD-mediated Protein Replacement Therapy emerges as a suitable model system for the therapeutic approach for mitochondrial disorders.

show abstract

Pancreatic Extracts in The Treatment of Diabetes Mellitus

Cited by 165 publications

References 1 publication

History of islet transplantation

History of islet transplantation

Insulin Transport into the Brain and Cerebrospinal Fluid

Transduction of Human Recombinant Proteins into Mitochondria as a Protein Therapeutic Approach for Mitochondrial Disorders

Contact Info

Product

Resources

About